Takeda updates ADZYNMA labeling in U.S.; Boxed Warning: risk of neutralizing antibodies.
Takeda updates ADZYNMA labeling in U.S.; Boxed Warning: risk of neutralizing antibodies. Takeda Provides Update on ADZYNMA (ADAMTS13, recombinant-krhn) Takeda Provides Update on ADZYNMA (ADAMTS13, recombinant-krhn) Updated as of August 24, 2026 (originally published November 21, 2025) The health and safety of the patients we serve is our top priority. As such, in alignment with the U.S. Food and Drug Administration (FDA), we have updated the U.S. Prescribing Information for ADZYNMA® (ADAMTS13, recombinant-krhn) to include a Boxed Warning on the potential risk of developing neutralizing antibodies to ADAMTS13, as follows: ...